Advance in microRNA as a potential biomarker for early detection of pancreatic cancer

Biomarker Research

Table 2 The AUC, sensitivity and specificity of miRNA-based biomarkers for detection of pancreatic cancer

Item	Drived from	AUC		Sensitivity (%)		Specificity (%)		Reference
Item	Drived from	PCa vs. Normal	PCa vs. CP	PCa vs. Normal	PCa vs. CP	PCa vs. Normal	PCa vs. CP	Reference
miR-20a, 21, 24, 25, 99a, 185, 191	Serum	0.992		89		100		[13]
miR-10b, 155, 106b, 30c, 212	Plasma	>0.90		95		100		[14]
miR-10b, 155, 106b, 30c, 212	Bile	>0.90		96		100		[14]
miR-21, 210, 155, 196a	Plasma	0.82		64		89		[15]
CA19-9	Serum	0.903	0.897	81.2	81.2	100.0	89.0	[17]
miR-16, 196a,	Plasma	0.895	0.790	87.0	75.4	73.5	66.4
miR-16+miR-196a+CA19-9	-	0.979	0.956	92.0	88.4	95.6	96.3
PaCIC marker	Serum	-		0.96		0.86		[18]
miR-1246, 4644, 3976, 4306	Serum	-		0.81		0.94
PaCIC marker + miR-1246, 4644, 3976, 4306	Serum	-		1.00		0.80

Serum miR-20a, 21, 24, 25, 99a, 185 and 191 were derived from 197 PCa cases and 158 age- and sex-matched cancer-free controls. MiR-10b, 155, 106b, 30c and 212 were derived from patients (n = 215) with treatment-naive PDAC (n = 77), CP with bile/pancreatic duct pathology (n = 67), and controls (n = 71). The plasma levels of miR-21, 210, 155, 196a were interrogated in 49 PCa and 36 normal healthy individuals. Plasma miR-16, 196a and CA19-9 were extracted from 140 PCa patients, 111 CP patients and 68 normal controls. PaCIC marker and miR-1246, 4644, 3976, 4306 were collected from 20 healthy donors, 131 PCa, 25 CP, 22 benign pancreatic tumors, 12 nonPCa. PCa pancreatic cancer, CP chronic pancreatitis, AUC area under the curve, − No data was available in the instances

ISSN: 2050-7771